In vitro anti-NTHi activity of haemophilin-producing strains of Haemophilus haemolyticus by Atto, B et al.
 Pathogens 2020, 9, 243; doi:10.3390/pathogens9040243 www.mdpi.com/journal/pathogens 
Article 
In Vitro Anti-NTHi Activity of Haemophilin-
Producing Strains of Haemophilus haemolyticus 
Brianna Atto 1,*, Roger Latham 2, Dale Kunde 1, David A Gell 2 and Stephen Tristram 1,* 
1 School of Health Sciences, University of Tasmania, Newnham Drive, Launceston, TAS 7248, Australia; 
dale.kunde@utas.edu.au 
2 School of Medicine, University of Tasmania, 17 Liverpool Street, Hobart, TAS 7000, Australia; 
roger.latham@utas.edu.au (R.L.), david.gell@utas.edu.au (D.A.G.) 
* Correspondence: brianna.atto@utas.edu.au (B.A.); stephen.tristram@utas.edu.au (S.T.) 
Received: 27 February 2020; Accepted: 22 March 2020; Published: 25 March 2020  
Abstract: Nontypeable Haemophilus influenzae (NTHi) is a leading causative organism of 
opportunistic respiratory tract infections. However, there are currently no effective vaccination 
strategies, and existing treatments are compromised by antibiotic resistance. We previously 
characterized Haemophilus haemolyticus (Hh) strains capable of producing haemophilin (HPL), a 
heme-binding protein that restricts NTHi growth by limiting its access to an essential growth factor, 
heme. Thus, these strains may have utility as a probiotic therapy against NTHi infection by limiting 
colonization, migration and subsequent infection in susceptible individuals. Here, we assess the 
preliminary feasibility of this approach by direct in vitro competition assays between NTHi and Hh 
strains with varying capacity to produce HPL. Subsequent changes in NTHi growth rate and fitness, 
in conjunction with HPL expression analysis, were employed to assess the NTHi-inhibitory capacity 
of Hh strains. HPL-producing strains of Hh not only outcompeted NTHi during short-term and 
extended co-culture, but also demonstrated a growth advantage compared with Hh strains unable 
to produce the protein. Additionally, HPL expression levels during competition correlated with the 
NTHi-inhibitory phenotype. HPL-producing strains of Hh demonstrate significant probiotic 
potential against NTHi colonization in the upper respiratory tract, however, further investigations 
are warranted to demonstrate a range of other characteristics that would support the eventual 
development of a probiotic. 
Keywords: Haemophilus influenzae; Haemophilus haemolyticus; respiratory probiotic; respiratory 
infection; heme; heme-binding protein; otitis media; chronic obstructive pulmonary disease 
 
1. Introduction 
The bacterium nontypeable Haemophilus influenzae (NTHi) is commonly associated with upper 
respiratory tract (URT) colonization in healthy adults [1]. However, migration to other sites in the 
respiratory tract frequently occurs in children, the elderly and individuals with underlying 
respiratory diseases; making NTHi a leading cause of mucosal infections [2]. In particular, enormous 
global morbidity is attributed to otitis media and exacerbations of chronic obstructive pulmonary 
disease, which are accompanied by long-term health complications and considerable mortality, 
respectively [3,4]. NTHi has also gained attention as an increasingly important cause of invasive 
infections [5,6]. 
There are currently no effective vaccination strategies for the prevention of NTHi infections, and 
treatment has been complicated by the rapid development of antibiotic resistance to first- and second-
line antibiotics. Resistance is predominantly mediated by β-lactamase production [7]; however, the 
emergence and spread of β-lactamase-negative, ampicillin-resistant strains in many regions of the 
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world is of substantial concern with treatment failure also being reported in response to macrolides 
[8–10] and fluoroquinolones [11–13].  
NTHi infection is preceded by successful colonization of the URT, and survival in this 
environment relies on the bacterium’s ability to acquire the vital growth factor, heme [14]. There is 
also evidence to suggest heme acquisition genes are important modulators of NTHi virulence factors 
[15], demonstrated by the increased prevalence in disease-causing strains from the middle ear, 
compared with colonizing throat strains [14]. Deletion of multiple genes related to heme-iron 
scavenging, utilization and regulation has been shown to significantly reduce NTHi virulence, 
disease severity and duration in animal models of otitis media [16,17]. Similarly, an isogenic mutant 
of two heme acquisition pathways was unable to sustain bacteraemia or produce meningitis in a rat 
model of invasive disease [18]. Thus, heme acquisition pathways represent potentially high value 
targets for the development of novel therapies for the eradication of NTHi from the respiratory tract 
[19,20]. 
NTHi is particularly susceptible to heme restriction as it lacks the necessary enzymes for its 
synthesis and relies solely on scavenging heme from the host, either in the form of free heme or bound 
to host carrier molecules [16,21–23]. Evidence from our laboratory suggests that closely related 
commensals may present a competitive challenge for heme acquisition in the URT. Previously, we 
discovered Haemophilus haemolyticus (Hh) strains that exhibited inhibitory activity against NTHi 
[24,25]. Further investigation revealed this inhibition was mediated by the production of a heme-
binding protein, haemophilin (HPL), that restricted NTHi growth by limiting its access to heme [25]. 
Thus, these strains may have utility as a probiotic therapy against NTHi infection by limiting 
colonization, migration and subsequent infection in susceptible individuals. Hh strains with anti-
NTHi properties have other characteristics that support their potential use as probiotics. Firstly, they 
share the same upper respiratory niche as NTHi [1] and more importantly, although they have 
occasionally been reported as pathogens of sterile sites in immunocompromised patients [26], there 
is convincing evidence that they are not opportunistic pathogens of the respiratory tract [27–29]. 
Here, we aim to determine the potential of a future probiotic approach by assessing in vitro 
competition between NTHi and Hh strains with varying capacity to produce HPL.  
2. Results and Discussion 
2.1. Validation of a Triplex Real-Time PCR for Quantification of NTHi, Hh and Detection of HPL 
The HPL amplicon was confirmed to be specific and sensitive for the detection of the five 
previously identified HPL sequence variants [25] by in silico investigations and by PCR. Specificity 
of the HypD and SiatT targets was also confirmed by PCR. Complete results of PCR assay validation 
are detailed in supplementary materials (S2.1.). The low limit of quantification values for the HypD 
and SiaT assays in triplex format were 2 × 10-5 ng and 2 × 10-4 ng, corresponding to 10 and 100 GE, 
respectively. The lower limit of detection for the HPL assay was 10 GE (Figure S1). The upper limits 
of detection/quantification were not explicitly determined as expected DNA levels from sample were 
unlikely to exceed the maximum 2 ng tested.  
Given the high volume of samples generated from growth experiments, a cheap and high-
throughput gDNA extraction method was required to reliably distinguish and quantify NTHi and 
Hh in co-culture. Extraction utilizing thermal lysis has previously been shown to be an efficient and 
cost-effective method to harvest bacterial gDNA for quantitative real-time PCR from suspensions of 
several bacterial species in a range of sample matrices [30–35]. Crude DNA extraction methods are 
also prone to contamination with PCR inhibitors originating from sample matrices [33,36]. There are 
also reports of intra- and inter-species differences in DNA extractions efficiencies [33,36,37]. PCR 
quantification of gDNA extracted by thermal lysis was validated and found to be comparable to 
quantification by OD600 and colony counts (Figure S4). Complete results of thermal extraction 
validation, including detection of PCR inhibitors (Figure S2) and extraction efficiency (Figure S3) are 
available in supplementary materials (S2.2.).  
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2.2. Baseline NTHi-Inhibitory Activity of Hh Strains Containing the HPL ORF 
We previously identified clinical isolates of Hh with several different HPL open reading frame 
(ORF) sequences and variable inhibitory activities even between strains containing identical HPL 
ORF sequences (Table S1) [25]. In order to determine the basis of this phenotypic variation and predict 
inhibitory potential, selection of Hh strains (Hh-RHH122, Hh-NF4 and Hh-NF5) for investigation 
was based on identical sequence similarity to the Hh-BW1 HPL ORF, previously identified as having 
the highest NTHi-inhibitory activity [25]. Based on results from the well diffusion assay, isolates Hh-
BW1, Hh-RHH122 and Hh-NF5 were categorised as having the Hh-HPL+ phenotype; no inhibitory 
activity was detected from Hh-NF4 broth supernatants, categorising it as Hh-HPL-. Hh strains that 
did not possess the HPL ORF (Hh ATCC 33390 and Hh-BW1HPL-KO) were confirmed to be Hh-HPL-. 
The degree of inhibitory activity varied between the Hh-HPL+ isolates and was comparably highest 
in Hh-BW1 and Hh-RHH122, approximately twice the activity measured for Hh-NF5 (Figure S5).  
2.3. HPL Expression Correlates with the Hh-HPL+ Phenotype 
Given that HPL ORF sequence identity was not predictive of NTHi-inhibitory capacity, baseline 
expression of HPL was investigated. The hypD target was validated as the housekeeper gene (Figure 
S6A), and the optimal growth phase for HPL expression analysis was determined (Figure S6B). 
Baseline expression of HPL was highest in Hh-BW1 and Hh-RHH122, significantly lower in Hh-NF5 
(p <0.0001), and completely absent in Hh-NF4 (Figure 1). Expression patterns correlate with the 
NTHi-inhibitory capacity of Hh strains, suggesting a connection between expression of HPL and the 
NTHI-inhibitory phenotype resulting from production of the HPL protein. 
 
Figure 1. Baseline HPL expression. PCR-quantified expression of HPL for Haemophilus haemolyticus 
(Hh) strains containing identical HPL open reading frames (ORFs) (relative to Hh-BW1HPL-KO). Data 
points are represented as mean +/- SEM of four biological replicates, performed from duplicate RNA 
extractions. 
2.4. The Hh-HPL+ Phenotype Confers a Competitive Advantage against NTHi  
A co-culture assay was used to test the ability of Hh with different levels of HPL production to 
compete with NTHi. The growth rate of NTHi was significantly impaired during competition with 
all Hh-HPL+ strains, compared with growth without competition (p < 0.0001) (Figure 2A). This 
inhibitory effect was more pronounced during competition with strains Hh-BW1 and Hh-RHH122, 
compared with Hh-NF5, replicating inhibitory patterns observed in the well diffusion assay. The 
growth rate of NTHi during competition with Hh-HPL– was not significantly affected (Figure 2A), 
suggesting that the inhibitory effect observed was a unique characteristic of Hh-HPL+ strains. Loss of 
the Hh-HPL+ phenotype in Hh-BW1HPL-KO, compared with the wild-type Hh-BW1, is evidence for a 
causative effect of the HPL gene on competition. Correlation between competition outcomes and HPL 
Pathogens 2020, 9, 243 4 of 11 
gene expression in Hh-BW1, Hh-RH122, Hh-NF5 and Hh-NF4 strains is also consistent with a 
hypothesis that strains with higher HPL expression compete with NTHi more effectively. 
For commensals and pathogens living in or invading human tissues, iron-containing heme is 
often a limiting nutrient, particularly in the respiratory tract where concentrations are considered to 
be low [38]. This is particularly true for heme auxotrophs including NTHi and Hh; for these species’ 
survival in the URT niche is dependent on their ability to outcompete host proteins and co-existing 
bacterial populations for heme [16]. We previously demonstrated that the NTHi-inhibitory 
mechanism of HPL is associated with it’s ability to bind heme in a form inaccessible to NTHi and that 
inhibitory activity is lost in conditions where heme concentration exceeds the binding capacity of 
HPL [25]. While levels of heme/iron are considered to be low in the respiratory tract, there is indirect 
evidence for increased levels in airways of smokers, chronic obstructive pulmonary disease and cystic 
fibrosis, which may contribute to increased susceptibility to infection in these individuals [38]. Thus, 
it was important to assess the effectiveness of HPL with varying concentrations of heme to ensure 
inhibitory effect in a range of in vitro conditions reflecting possible in vivo scenarios. The NTHi-
inhibitory capacity of HPL was maintained even in conditions of high heme availability (15 µg mL-
1), albeit to a lesser degree than lower heme concentrations (0.0–3.8 µg mL-1) (Figure 2A). This 
suggests that levels of HPL produced by Hh are sufficient to limit NTHi’s access to heme in a dynamic 
in vitro system, even under excess heme conditions unlikely to be encountered in vivo [38].  
Figure 2. Short-term competition between Haemophilus influenzae (NTHi) and Hh. Calculated growth 
rates of NTHi in response to competition with (A) Hh-HPL+ or (B) Hh-HPL-. The growth rate for each 
(C) Hh-HPL+ and (D) Hh-HPL- strain was also determined. Data points represented as mean +/- SEM 
of three separate experiments, performed in triplicate; p < 0.05*, p < 0.005 **, p < 0.0005 ***, p < 0.0001 ****. 
2.5. The Hh-HPL+ Phenotype is Associated with a Growth Advantage  
Interestingly, all Hh-HPL+ strains exhibited a pattern of enhanced growth in response to NTHi 
competition (p < 0.0001) (Figure 2C). This effect was maintained across all heme concentrations and 
was more pronounced for Hh-BW1 and Hh-RHH122. The converse was observed in Hh-HPL- strains 
that appeared to experience poorer growth in response to competition with NTHi (Figure 2D). This 
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indicates that NTHi is able to outcompete Hh only in the absence of the Hh-HPL+ phenotype, which 
may be a reflection of the highly efficient set of heme-scavenging systems possessed by NTHi.  
Given the correlation between competition outcomes and HPL gene expression, expression 
analysis was performed on Hh during competition with NTHi, relative to growth without 
competition. Upregulation of HPL was observed in all Hh-HPL+ in response to competition with 
NTHi, an effect that was more pronounced in Hh-BW1 and Hh-RHH122 (Figure 3). This may explain 
the enhanced growth rate of Hh-HPL+ strains in response to NTHi during the short-term competition 
assays (Figure 2C).  
 
Figure 3. HPL expression during competition. PCR-quantified expression of HPL during competition 
with NTHi relative to individual growth. Data points are represented as mean +/- SEM of four 
biological replicates, performed from duplicate RNA extractions. 
These results show that expression of HPL has a significant impact on the NTHi-inhibitory 
capacity of Hh-HPL+ strains and eventual therapeutic utility in an in vivo setting. Therefore, the huge 
differential expression of HPL amongst Hh-HPL+ strains must be considered in the future when 
selecting a potential probiotic candidate for further evaluation. However, our understanding of HPL 
regulation is still rudimentary. Further investigation into potential upstream regulatory components 
or post-translational modification is needed to elucidate the inter-strain differences in HPL 
production and/or biological activity despite complete ORF sequence identity.  
2.6. NTHi Fitness Dramatically Decreases during Extended Co-Culture with Hh-HPL+ 
Short-term competition may highlight the potency of HPL-mediated inhibition but is not 
representative of in vivo competition dynamics. Thus, a longer-term study was employed to assess 
the competition between NTHi and Hh-HPL+ over a period of 6 days (12 generations). The 
competitive advantage of Hh-HPL+ strains was evident within the 2nd generation (24 h) for Hh-BW1 
and Hh-RHH122 and 4th generation (48 h) for Hh-NF5 (Figure 4A). Speculatively, the stunted 
inhibitory activity exhibited by Hh-NF5 may be due to the lower HPL expression levels exhibited by 
this strain, resulting in slower accumulation of HPL over the course of the assay. The fitness of NTHi 
over subsequent generations decreased significantly until complete loss of fitness during the final 
generations. Competition with Hh-HPL- strains did not significantly affect the overall fitness of any 
of the NTHi strains over the 6 day period. However, a small decrease in NTHi fitness was observed 
after 24 h, followed by complete recovery (Figure 4A). This may have arisen from competition for 
heme prior to the onset of maximum HPL production. 
To show that loss of fitness of NTHi was not unique to NTHi strain ATCC 49247, additional 
reference strains NCTC 11315 and ATCC 49766 were tested in competition with Hh-BW1. All three 
NTHi strains responded in the same manner, culminating in a total loss of NTHi fitness at the end of 
the 6 day period (Figure 4B). 
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Figure 4. Fitness of NTHi strains during co-culture with Hh. Calculated fitness of NTHi in response 
to competition with Hh-HPL+ or Hh-HPL- relative to growth of the competitor strain. (A) Competition 
between a single NTHi strain and multiple Hh, or (B) multiple NTHi against Hh-BW1. Data points 
represented as mean +/- SEM of three separate experiments, performed in quadruplicate. 
3. Materials and Methods 
3.1. Bacterial Growth Conditions  
3.1.1. Bacterial Strains  
Hh strains used in this study (BW1, RHH122, NF1, NF4 and NF5) have previously been isolated 
and screened for the HPL open reading frame (ORF) [24,25]. An HPL knockout (BW1HPL– KO) of the 
model HPL-producing strain of Hh (Hh-BW1), constructed using insertional inactivation as 
previously described [25], and Hh ATCC 33390 (PCR negative for the HPL ORF) were included as 
noninhibitory controls. NTHi strains were ATCC 49247, ATCC 49766 and NCTC 11315. 
NTHi and Hh isolates were propagated from liquid nitrogen frozen glycerol stock, followed by 
two overnight passages on chocolate agar (CA) at 37 °C with 5%–10% CO2 prior to experimentation. 
Strains were grown in supplemented Tryptone Soy Broth (sTSB), which consisted of tryptone soy 
broth (TSB) (Oxoid Ltd., Basingstoke, UK) supplemented with 2% (v/v) Vitox® (Oxoid Ltd.) and 15 
µg mL-1 of porcine hematin (ferriprotoporphyrin IX hydroxide, Sigma-Aldrich). Exposure to 
nongrowth conditions was minimized by maintaining suspensions and diluents at 37 °C.  
3.1.2. Propagation of Heme-Replete Populations for Growth Experiments 
Strains were propagated under heme-replete conditions prior to use in competition experiments 
to replenish bacterial heme stores and minimise external stressors that may influence the outcome of 
competitive growth [25,39,40]. Bacterial suspensions of ~1.0 OD600 were made in TSB from 8–10 h 
growth on CA and diluted 1:10 in pre-warmed sTSB (5 mL). Broths were incubated for 12 h at 37 °C 
aerobically with shaking (220 RPM), centrifuged at 4000 × g for 5 min at 37 °C and resuspended in 
fresh, pre-warmed TSB to an OD600 of 1.0 prior to use in growth experiments.  
3.2. Determination of NTHi-Inhibitory Activity 
A well diffusion assay of broth supernatants was used to categorise Hh strains containing the 
HPL ORF as either inhibitory to NTHi (Hh-HPL+) or noninhibitory (Hh-HPL–), as previously 
described [24]. This assay was also used to establish the relative inhibitory activity of each strain. 
Testing was conducted on two indicator NTHi strains (ATCC 49427 and clinical isolate NTHi-L15). 
Media supernatants from strains negative for the HPL ORF (Hh ATCC 33390 and Hh-BW1HPL– KO) 
were included as controls. 
3.3. Triplex Real-Time PCR for the Quantification of NTHi, Hh and Detection of HPL 
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A real-time quantitative triplex PCR assay was designed to quantify NTHi, Hh and detect the 
HPL ORF. The targets used for discrimination of Hh (hypD) and NTHi (siaT) have previously been 
described and validated [41]. For detection of the HPL ORF, primers were designed based on the HPL 
ORF of Hh-BW1 (GenBank MN720274) [25]. The FAM, HEX and TET channels were used for 
simultaneous fluorescence detection of siaT, hypD and HPL, respectively. Primer and probe sequences 
are detailed in Table 1. Primer specificity was confirmed by discontiguous megaBLAST analysis and 
PCR of a panel of Haemophilus spp. and multiple genera representing common URT flora. PCR assays 
were extensively optimised and evaluated for detection/quantification limits in triplex format.  
Table 1. Summary of primer and LNA probe sequences, and expected amplicon size for the hypD, 
siaT and HPL targets. 
Primers and 
Probes 
Sequence 
Amplicon Size 
(bp) 
hypD Forward 5′- GGCAATCAGATGGTTTACAACG 
187 
hypD Reverse 5′- CAGCTTAAAGYAAGYAGTGAATG 
hypD LNA-
probe 
/5HEX/CCA+C+AA+C+GA+G+AATTAG/3IABkFQ/ 
siaT Forward 5′- AATGCGTGATGCTGGTTATGAC 
138 siaT Reverse 5′- AATGCGTGATGCTGGTTATGAC 
siaT LNA-probe /56-FAM/A+GA+A+GCAGC+A+G+TAATT/3IABkFQ/ 
HPL Forward 5′- TATTCCTAATGATCCCGCT 
120 
HPL Reverse 5′ - TCTTTTTTCGCTACCCCT 
HPL LNA-
probe 
/5Cy5/AT+CCATTTA+TCGG+CACGTTCT/3IAbRQSp/ 
PCRs were performed using the CFX96 TouchTM real-time PCR system (Bio-Rad) in 96-well 
optical plates. Polymerase activation was performed at 95 °C for 3 min, followed by 40 amplification 
cycles of denaturation at 95 °C for 15 s, and annealing at 62 °C for 1 min. Each reaction contained 0.25 
µM of hypD, siaT and HPL primers, 0.1 µM LNA probes, 1× PrimeTime master mix (Integrated DNA 
Technologies) and 5 µL gDNA and molecular-grade water, to a total volume of 20 µL. Template 
gDNA was prepared by a thermal extraction protocol and tested in duplicate. Each run included a 
positive control for the HPL ORF (Hh-BW1), negative control (H. parainfluenzae ATCC 7901), no-
template control and 10-fold dilutions of a standard containing 2 × 10-8 ng NTHi ATCC 49247 and Hh 
ATCC 33390 gDNA. Quantification of NTHi and Hh was expressed as genome equivalents (GE) 
calculated from the standard, as previously described [41]. Bacterial quantification from thermally 
extracted gDNA was validated against conventional bacterial quantification by optical density and 
colony counts.  
Complete details of PCR primer design, assay optimisation and gDNA extraction protocol 
evaluation are available in supplementary material (S1.). 
3.4. Competition Assays  
3.4.1. Short-Term Broth Competition  
Culture mixes were prepared by adding 100 µL of heme-replete preparations of a single Hh 
strain (Hh-BW1, Hh-BW1HPL-KO, Hh-RHH122, Hh-NF4, Hh-NF5 or ATCC33390) together with 100 µL 
of NTHi ATCC 49247 to 5 mL pre-warmed sTSB containing 0.0, 0.9, 3.8 or 15.0 ug mL–1 porcine 
hematin. Broths containing single strains were also prepared in parallel to determine baseline growth. 
Broths were incubated aerobically on an incubator shaker at 37 °C (220 RPM) for 16 h. At different 
time intervals, aliquots of 50 µL were taken for thermal gDNA extraction and subsequent triplex PCR 
quantification of GE. Aliquots of 500 µL were taken at 8 h for quantification of HPL expression. Purity 
of broth growth was checked by plating on CA after 16 h incubation.  
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Statistical comparisons were made between strains grown with a competitor and baseline 
growth by calculating the change in the number of cells per hour (growth rate) using the following 
formula: 
  
  
  
=   (  −   ) 
where Nt is the number of cells (measured as GE) at time t, N0 is the number of cells at time zero (t0), 
and α is the growth rate where units are determined by the units of t.  
3.4.2. Fitness Assay 
Culture mixes were prepared by adding 100 µL of heme-replete preparations of each of the Hh 
strains and 100 µL of NTHi (ATCC 49247, ATCC 49766 or NCTC 11315) to 5 mL of pre-warmed sTSB 
containing 0.0, 0.9, 3.8 or 15.0 µg mL–1 porcine hematin. Broths were incubated aerobically on an 
incubator shaker at 37 °C (220 RPM) for 12 h prior to subculture (200 µL) in fresh sTSB (2 mL) 
containing the same concentration of heme as the inoculum. The process of 12 hourly incubation 
followed by subculture into fresh broth was repeated until 6 days had elapsed. After each 12 h 
incubation, aliquots of 50 µL were taken for boiled gDNA extraction and subsequent triplex PCR 
quantification of GE. Purity of broth growth was confirmed by plating on CA after each 12 h 
incubation. Fitness of NTHi at each time point was determined using the following equation [42]: 
  =  
  (
  
   
)
  (
  
   
)
 
where w is fitness, A and B are the population sizes of the two competitors, subscripts t0 and t indicate 
the initial and final time points in the assay. Growth after the first 12 h culture was used as baseline 
for fitness determination (t0).  
3.5. Expression Analysis  
3.5.1. RNA Extraction, Purification and Quantification 
Aliquots taken from broth growth were immediately added to two volumes of RNAprotect 
Bacteria Reagent (Qiagen) for immediate stabilization of bacterial RNA. Stabilized aliquots were 
normalized to an OD600 of 0.05 (approximately 5 × 107 cells), pelleted by centrifugation for 10 min at 
5000 × g and stored at -20 °C overnight. Bacterial lysates were prepared by resuspending pellets in 
100 µl TE buffer (30mM Tris-Cl, 1 mM EDTA, pH 8.0) containing 15 mg mL-1 lysozyme and 20 µL 
proteinase K, vortexed and incubated at room temperature in an incubator shaker (1000 RPM) for 1 
h. Following addition of 350 µL buffer RLT, samples were vortexed and centrifuged at 20000 × g for 
2 min. The supernatant was purified following the manufacturers protocol for RNeasy Plus Mini Kit, 
which was semiautomated by the QIAcube (Qiagen). The iScriptTM cDNA Synthesis Kit (Bio-Rad) was 
used to produce cDNA for subsequent PCR. The validated triplex PCR was used to determine 
expression of HPL ORF in Hh strains, using hypD as the housekeeper gene. 
3.5.2. Expression Validation 
Expression analysis was employed to determine baseline expression and suitability of 
prospective competitive test conditions for HPL expression. Given the kinetics of bacterial growth 
and the heme-binding capacity of HPL, time and heme availability were targeted as factors that may 
influence HPL expression. The hypD target was selected as a potential housekeeper gene and 
validated for test conditions.  
To validate expression analysis, heme-replete preparations of Hh-BW1 and the Hh-BW1HPL– KO 
(100 µL) were added to 5 mL pre-warmed sTSB containing either 0.0 or 15.0 µg ml-1 of porcine 
hematin. Broths were incubated for 8 h, and aliquots of 500 µL were removed for RNA extraction and 
Pathogens 2020, 9, 243 9 of 11 
purification at 0, 4 and 8 h. Following validation, baseline HPL expression was quantified for isolates 
Hh-BW1, Hh-RHH122, Hh-NF4 and Hh-NF5 relative to Hh-BW1HPL– KO from 8 h growth in sTSB 
without porcine hematin.  
3.6. Statistical Analysis  
Statistical analysis was performed using GraphPad Prism V7.04, 2017. Statistical significance 
was determined by comparison of growth data (growth rate or fitness) between strains grown with 
a competitor and baseline growth. Data were tested for normality using the Shapiro–Wilk test, 
followed by a two-way ANOVA with Dunnett’s multiple comparison test. Expression ratios and 
statistical significance were calculated with 2000 iterations by the Relative Expression Software Tool 
(REST; v 1.0, 2009) [43,44].  
4. Conclusion 
Previously, we identified an uncharacterized hemophore (designated HPL) produced by Hh 
which was able to inhibit NTHi growth by heme starvation [25]. Here, we aimed to further test the 
inhibitory capacity of Hh-HPL+ strains by direct in vitro competition with NTHi, for the purpose of 
determining their probiotic potential. These results provide a strong link between the NTHi-
inhibitory phenotype, HPL expression and favourable outcomes during competitive growth with 
NTHi in vitro. Thus, Hh-HPL+ strains exhibit promising probiotic potential against NTHi 
colonization in the URT. Reduction or elimination of NTHi carriage from the URT proposes an 
effective means of limiting migration and subsequent infection in susceptible individuals. However, 
significant further investigation is required to determine if the inhibitory capacity demonstrated in 
this study extends to more complex models of NTHi colonisation and infection, such as cell culture 
systems and animal models. Further, studies investigating the safety profile of Hh-HPL+ strains and 
their ability to colonise the host are also required before the probiotic potential of such strains can be 
advanced. 
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